Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design

Jing Yan; Hao Zhang; Guangfeng Li; Jiacan Su; Yan Wei; Can Xu

Acta Pharmaceutica Sinica B (Feb 2024)

Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design

Jing Yan,
Hao Zhang,
Guangfeng Li,
Jiacan Su,
Yan Wei,
Can Xu

Affiliations

Jing Yan: Institute of Translational Medicine, Shanghai University, Shanghai 200444, China; Institute of Medicine, Shanghai University, Shanghai 200444, China
Hao Zhang: Institute of Translational Medicine, Shanghai University, Shanghai 200444, China; Department of Orthopedics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
Guangfeng Li: Department of Orthopedics, Shanghai Zhongye Hospital, Shanghai 200941, China
Jiacan Su: Institute of Translational Medicine, Shanghai University, Shanghai 200444, China; Department of Orthopedics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China; Organoid Research Center, Shanghai University, Shanghai 200444, China; Corresponding authors.
Yan Wei: Institute of Translational Medicine, Shanghai University, Shanghai 200444, China; Organoid Research Center, Shanghai University, Shanghai 200444, China; Corresponding authors.
Can Xu: Department of Gastroenterology, Changhai Hospital, Shanghai 200433, China; Corresponding authors.

Journal volume & issue: Vol. 14, no. 2
pp. 579 – 601

Abstract

Read online

Lipid nanovehicles are currently the most advanced vehicles used for RNA delivery, as demonstrated by the approval of patisiran for amyloidosis therapy in 2018. To illuminate the unique superiority of lipid nanovehicles in RNA delivery, in this review, we first introduce various RNA therapeutics, describe systemic delivery barriers, and explain the lipid components and methods used for lipid nanovehicle preparation. Then, we emphasize crucial advances in lipid nanovehicle design for overcoming barriers to systemic RNA delivery. Finally, the current status and challenges of lipid nanovehicle-based RNA therapeutics in clinical applications are also discussed. Our objective is to provide a comprehensive overview showing how to utilize lipid nanovehicles to overcome multiple barriers to systemic RNA delivery, inspiring the development of more high-performance RNA lipid nanovesicles in the future.

Published in Acta Pharmaceutica Sinica B

ISSN: 2211-3835 (Print); 2211-3843 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b

About the journal

Abstract

Keywords